1. Medtech Insight
  2. >>Policy & Regulation

US Insurers, Hospitals, Medtech Industry Say Transparency Rule Touted In President’s Speech Is Anticompetitive

Trump says transparency rule ‘bigger than health care reform’ while hospitals file suit against it

 
• By Sue Darcey

US President Donald Trump in his State of the Union address on 4 February touted his 2019 Price Transparency executive order calling on federal agencies to require private hospitals and insurers to publicly reveal the costs of hundreds of their device-related procedures and lab tests – as well as insurers’ negotiated rates for them – so patients can shop for their own health care. But industry maintains the resulting rules out of the Centers for Medicare and Medicaid Services are “anticompetitive,” and a coalition of hospital groups is suing the Department of Health and Human Services to stop their implementation.

Trump_Donald_160716_1200x675

The medtech, hospital and insurance industries are all questioning a hospital and insurance coverage price transparency executive order (EO) promoted by the President Trump during his 4 February State of the Union address – a proposal that inspired more than 25,000 Americans to flood the US Centers for Medicare and Medicaid Services (CMS) with comments on the high cost of medical care.

Hospital trade groups are also suing the Department of Health and Human Services (HHS) over the resulting twin regulations, saying they exceed the department’s legal authority, abridge free speech and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Medtech Insight

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By Shubham Singh

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 
• By Brian Bossetta

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.